These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9781067)

  • 21. Interleukin-2 in metastatic melanoma: what is the current role?
    Atkins MB
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S8-10. PubMed ID: 10685651
    [No Abstract]   [Full Text] [Related]  

  • 22. Mucosal melanoma.
    Seigler HF
    J Surg Oncol; 2004 Jul; 86(4):187-8. PubMed ID: 15221925
    [No Abstract]   [Full Text] [Related]  

  • 23. Malignant melanoma: an update on treatments.
    Black J
    Plast Surg Nurs; 1999; 19(3):143-7. PubMed ID: 10765299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete remission seven years after treatment for metastatic malignant melanoma.
    Petit T; Janser JC; Petit JC
    Cancer; 1996 Aug; 78(3):571. PubMed ID: 8697410
    [No Abstract]   [Full Text] [Related]  

  • 25. Case of renal metastasis of melanoma successfully controlled by a combination therapy of nivolumab and radiation.
    Kasuya A; Fukuchi K; Sano Y; Tatsuno K; Kitano S; Ishibe J; Fujiyama T; Tokura Y
    J Dermatol; 2018 Sep; 45(9):e246-e247. PubMed ID: 29574914
    [No Abstract]   [Full Text] [Related]  

  • 26. Malignant melanoma.
    Califano J; Nance M
    Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine-based therapy for melanoma: pre-clinical studies.
    Shurin MR; Kirkwood JM; Esche C
    Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological response modifiers in melanoma.
    Bridgewater JA; Gore ME
    Br Med Bull; 1995 Jul; 51(3):656-77. PubMed ID: 7552087
    [No Abstract]   [Full Text] [Related]  

  • 29. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
    Pappo I; Lotem M; Klein M; Orda R
    Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated malignant melanoma. New therapeutic approaches.
    Stadler R; Garbe C
    Int J Dermatol; 1991 Apr; 30(4):239-42. PubMed ID: 1711019
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term survival of a patient with melanoma with late recurrence of pulmonary metastasis treated by repeat surgery].
    Ferri RM; Thomas P; Tramier H; Guidicelli R; Kleisbauer JP
    Rev Mal Respir; 1999 Apr; 16(2):204-5. PubMed ID: 10339764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 33. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
    Richtig E; Ludwig R; Kerl H; Smolle J
    Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ethical limits of the current treatment of melanoma].
    Bonérandi JJ
    Ann Dermatol Venereol; 1993; 120(6-7):435-6. PubMed ID: 8279786
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
    Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
    Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimodality management of brain metastases in metastatic melanoma patients.
    Samlowski WE; Jensen RL; Shrieve DC
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1699-705. PubMed ID: 18062744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidisciplinary treatment of primary melanoma.
    Yao K; Balch G; Winchester DJ
    Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of malignant melanoma].
    Helsing P
    Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2916-7. PubMed ID: 15550966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.